The peptide research universe, mapped.
Peptide science moves faster than the evidence behind it, marketing claims outrun the trials, and regulatory status shifts from one quarter to the next.
Compound Universe Genome is an independent peptide research project that maps each compound’s evidence chain: mechanism of action, study model, human outcomes, safety signals, and regulatory status.
Primary literature
Research traced to PubMed, original DOIs, trials, and regulators.
Evidence classified
Human, animal, in-vitro, and regulatory evidence kept distinct.
Limits disclosed
Uncertainty, weak study design, and missing safety data stay visible.
No peptide sales
An informational research project with no product storefront.
A navigable genome of peptide evidence.
Compound Universe Genome publishes evidence-tiered research profiles for peptides, peptide therapeutics, and investigational signaling compounds.
Compound Universe Genome grades every claim by the study model that produced it, separating what a laboratory assay showed from what a randomized controlled trial proved.
Compound Universe Genome tracks each compound’s regulatory position against FDA and Federal Register records, dated and by jurisdiction. Nothing on this site is for sale.
Every research profile answers five questions
What is the peptide or compound?
How is it proposed to work?
What has actually been studied?
What are the known risks and unknowns?
What is its current regulatory status?
Peptide science across biological systems
CU-Genome organizes the literature by biological system, because a compound’s evidence quality rarely travels between them. A peptide with human trial data for one outcome is often animal-only for another.
Healing and recovery
BPC-157, TB-500, and thymosin beta-4 research across tendon models, wound healing, angiogenesis, and gastrointestinal repair.
Weight and metabolism
GLP-1, GIP, and glucagon receptor agonism, obesity trials, glycemic control, appetite signaling, and body composition.
Skin and hair
GHK-Cu, copper peptides, collagen, extracellular-matrix biology, skin remodeling, and hair-follicle research.
Muscle and performance
Growth-hormone secretagogues, GHRH analogs, lean mass, exercise physiology, and recovery evidence.
Brain, sleep, and cognition
Semax, Selank, and DSIP research across neuroprotection, mood, circadian biology, and cognition.
Immune and inflammation
Thymosin alpha-1, KPV, and LL-37 across immune signaling, host defense, and preclinical models.
Sexual health
PT-141 and kisspeptin studies covering melanocortin signaling, desire, arousal, and reproductive biology.
Aging and longevity
Epithalon, MOTS-c, and SS-31 across cellular senescence, mitochondrial biology, and translational limits.
Widely researched and discussed peptide compounds
Semaglutide activates the GLP-1 receptor. Tirzepatide targets both the GIP and GLP-1 receptors. GHK-Cu binds copper and signals dermal fibroblasts. Sermorelin stimulates the pituitary through the GHRH receptor.
Approved medicines, discontinued drugs, clinical-stage candidates, and research-only compounds are never presented as equivalent.
BPC-157Preclinical tissue-repair research
GHK-CuCopper tripeptide, matrix biology
TB-500Thymosin beta-4 fragment
TesamorelinGHRH analog, FDA-approved
SermorelinGHRH analog, 503A compoundable
IpamorelinSelective GH secretagogue
RetatrutideInvestigational triple agonist
SemaglutideGLP-1 receptor agonist
TirzepatideDual GIP and GLP-1 agonist
PT-141Melanocortin agonist, FDA-approved
Thymosin alpha-1Immune-modulating peptide
CJC-1295Long-acting GHRH analog
Different studies answer different questions.
CU-Genome classifies claims by the type and maturity of the evidence behind them. This prevents an effect observed in isolated cells or rodents from being presented as an established human outcome.
In vitro
Experiments in cells, tissues, or isolated systems that explore mechanisms but cannot establish a clinical effect.
Animal
Preclinical models that may identify biological signals, safety concerns, or hypotheses requiring human validation.
Human
Observational studies, pharmacology research, and controlled trials, evaluated by design and outcome quality.
Regulatory
Approval labels, safety communications, and compounding decisions, dated to their jurisdiction.
Mechanisms, comparisons, safety, and status
Useful peptide research requires more than a list of potential benefits. Each finding sits inside a framework of evidence quality, pharmacology, safety, and legality.
How peptides interact with biology
Receptor activity, signaling pathways, half-life, bioavailability, metabolism, and the difference between a plausible mechanism and a demonstrated outcome.
Like-for-like evidence
Compounds compared by molecular target, study population, evidence maturity, measured outcomes, and regulatory position.
Status with a date and jurisdiction
FDA approval, compounding eligibility, prescribing rules, research status, and sporting restrictions are separate questions that change over time.
Evidence before excitement.
Every research summary shows what a study reports, how much confidence it deserves, and what it cannot establish.
01 / SOURCE
Start with primary literature
Original research, trial registries, PubMed records, DOIs, approved labels, and regulator documents take priority over commercial summaries.
02 / CLASSIFY
Label the evidence
Laboratory, animal, observational, controlled human, systematic-review, and regulatory evidence are identified separately.
03 / QUALIFY
Report the limitations
Small samples, weak controls, surrogate outcomes, conflicts, absent replication, and missing long-term safety data remain visible.
04 / MAINTAIN
Date material updates
New trials, approvals, safety communications, and regulatory decisions are incorporated with a visible review date.
Start with the evidence, not the marketing.
Every compound profile opens with what is established, what remains unproven, and where the regulatory line sits today.
Compound Universe Genome covers peptide therapeutics and research peptides across solid-phase peptide synthesis, amino acid sequence and molecular weight, receptor binding, half-life and bioavailability, GHRH analogs and growth-hormone secretagogues, melanocortin agonists, randomized controlled trials, meta-analyses, phase 2 and phase 3 data, ClinicalTrials.gov registrations, FDA approval status, 503A and 503B compounding, Category 2 listings, Pharmacy Compounding Advisory Committee review, Federal Register notices, research-use-only labeling, and WADA prohibited-list status.
Medical and regulatory disclaimer: Compound Universe Genome is an independent educational resource, not a medical provider, pharmacy, laboratory, or peptide seller. Content is informational only and is not medical advice, diagnosis, treatment, or a recommendation to obtain or use any substance. Many compounds discussed are investigational or are not approved for human use. Legal and regulatory status varies by jurisdiction and changes over time. Consult a qualified, licensed clinician for medical decisions.